Published in FDA Law Weekly, August 12th, 2004
Atrix's product is the AB-rated generic to topical Elocon Cream 0.1% which is marketed by Schering-Plough Corporation.
Elocon Cream is on patent until 2007. Pending the patent expiration and final FDA approval, Sandoz, Inc., a Novartis company, will market this new generic product cream.
"We are very happy with the tentative approval of this product," said David R. Bethune, chairman and chief executive officer...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of FDA Law Weekly